NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — Investor Presentation (August 2026)
20 slides from NovaBridge Biosciences's investor presentation, August 2026
Slide 1: Company Presentation
Company Presentation NASDAQ: NBP August 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewin
Slide 3: Bridging the gap between exceptional science and global patient impact
Bridging the gap between exceptional science and global patient impact A global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value The Opportunity NovaBridge Exceptional science is emerging We iden
Slide 4: Innovation is no longer the bottleneck, translation is
Innovation is no longer the bottleneck, translation is 2,227 ~85% New Molecule Entities are being developed in China Growth from Asia Up from ~78 in 2013; a 28× Of global innovative expansion in more than a decade pipeline in 2024 46% >$50B New Molecules from China China-Origin Deal Value Of all new
Slide 5: Three advantages drive NovaBridge's value-creation model
Three advantages drive NovaBridge's value-creation model Sophisticated Capital Privileged Allocation Access Development Expertise Discipline We access differentiated assets We develop and advance assets We deploy capital selectively and early through trusted ourselves across global markets, flexibly
Slide 6: A repeatable model for building sustainable value
A repeatable model for building sustainable value Each franchise applies a disciplined approach to sourcing, development, financing, and value creation Established Franchises Future Growth Platforms Givastomig Visara Europe Women’s Health Focused on GI cancers with Focused on retinal disease, with T
Slide 7: The NovaBridge model in action: Givastomig
The NovaBridge model in action: Givastomig Rapid development and multiple pathways to value Access Development Optionality Identified a differentiated Advanced givastomig from Created multiple pathways for CLDN18.2 opportunity Phase 1b to Phase 3 readiness in value realization through combining high
Slide 8: Givastomig: Exceptional clinical execution proof point
Givastomig: Exceptional clinical execution proof point Speed to Phase 3: 18 months from Phase 1b data (n=17) to Phase 3 initiation Asset Phase 1b Registration / Clinical POC Phase 3 stage Study Commercial Jul 2025 H1 2026 Oct 2026 As early as YE 2026 Jun 2028 ESMO GI Ph1b (n=17) Regulatory Milestone
Slide 9: Givastomig: Differentiated clinical profile
Givastomig: Differentiated clinical profile Clinical differentiation: Deep, durable activity in Phase 1b first-line gastroesophageal adenocarcinoma, with nivolumab and chemotherapy High response rates Broad biomarker activity Durable disease control ORR preserved across CLDN18.2 strata 77% 73% Claud
Slide 10: Givastomig: $5B+ peak sales potential across indications, if approved
Givastomig: $5B+ peak sales potential across indications, if approved Expanding from the 1L GEA to BTC and PDAC Indication expansion options Regimen Pivotal start Notes Peak sales HER2- | 1L metastatic | CLDN Giva + nivo + chemo 2026 Current lead indication $2B+ >=1, PD-L1 >=1 Expedites recruitment
Slide 11: The NovaBridge model in action: Visara
The NovaBridge model in action: Visara Target-product-profile driven asset sourcing, world-class expertise, and franchise creation in ophthalmology Access Development Optionality Identified high-conviction Built a world-class front and back Multiple pathways to value opportunity with differentiated
Slide 12: The first dual-targeting peptibody candidate designed to treat ocular neovascularization
The first dual-targeting peptibody candidate designed to treat ocular neovascularization Anti-VEGF-A Anti-VEGF-A VIS-101 • 2X the binding sites for VEGF-A Longer Durability Modified Higher Avidity Fc • 2X the binding sites for ANG-2 • Improved inhibitory activity compared to the industry leading Ant
Slide 13: Visara: Lead retinal asset with an expanding pipeline
Visara: Lead retinal asset with an expanding pipeline Front and back of the eye, targeting aggregate annual markets of more than $10 billion VIS-101 Pipeline Expansion Tetravalent VEGF / ANG-2 peptibody Two additional promising pipeline assets to replicate success Phase 2b expected to start in 2H 20
Slide 14: Extending the same repeatable model into new areas
Extending the same repeatable model into new areas Future growth built around the same principles: unmet need, differentiated assets, exceptional talent, and flexible value creation Europe Women's Health POSITIONING POSITIONING Applying the NovaBridge model to underserved Applying a target-product-p
Slide 15: Our vision and growth path
Our vision and growth path Creating a repeatable engine for turning exceptional science into patient impact Sustainable company Scale the playbook Next 5-10 years Establish the foundation Next 1-5 years Next 12 months Group level Hub level • Diversified 10+ asset portfolio • Expand clinical and BD c
Slide 16: NovaBridge at a glance
NovaBridge at a glance NBP Global 2 3 Nasdaq ticker Capabilities Proofs of execution Clinical-stage assets Publicly traded biotechnology United States, Europe and Asia Givastomig and VIS-101 Programs in active development company ~$216M NONE 700 Multiple Cash & equivalents Debt Assets screened Value
Slide 17: A differentiated clinical pipeline built on our global platform
A differentiated clinical pipeline built on our global platform REGISTRATIONAL/ ASSET/ TARGET INDICATION(S) REGIMEN PHASE 1 PHASE 2 NCT # MILESTONES PHASE 3 Giva + Chemo + Nivo vs. CLDN18.2 Positive/PD-L1 Positive NA Initiate as early as YE 2026 Chemo + Nivo Giva/Nivo/Chemo v. Phase 2 data CLDN18.2
Slide 18: $216m in cash and investments to support strategic inflection points
$216m in cash and investments to support strategic inflection points Maintained a strong debt-free balance sheet with ~$2161 million in cash and cash equivalents and investments at fair value, equity securities, as of June 30, 2026, providing runway through several important clinical and strategic i
Slide 19: Upcoming catalysts
VIS-101 Givastomig Ragistomig Upcoming catalysts Givastomig Initiate Phase 3 to support Accelerated Approval Pathway VIS-101 Givastomig VIS-101 Initiate Phase 2b Complete Phase 2 combo Initiate Phase 3 CLINICAL neovascular AMD study study enrollment for 1L neovascular AMD studies treatment of GEA US
Slide 20: Thank you
Thank you www.novabridge.com IR@novabridge.com
NovaBridge Biosciences — Investor Presentation (August 2026) on 6ix